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In patients with metastatic breast cancer, taxane treatment demonstrates activity but is not curative. Targeted treatment modalities
are therefore necessary in order to improve outcomes in this group. A randomized placebo-controlled phase II trial was initiated to
evaluate eﬀect and toxicity of geﬁtinib (250mg QD) and docetaxel 35mg/m2 (six of seven weeks) (NCT 00319618). The inclusion
of 66 patients was planned. The study was closed due to treatment-related toxicity. Of the 18 included patients, seven (of which
three received geﬁtinib) were withdrawn from the study due to toxicity. Of the nine patients receiving geﬁtinib and chemotherapy,
one achieved a partial response and four stable disease. In the chemotherapy of nine patients, four had a partial response and
four stable disease. The breast cancer patients in this study were genotyped using a panel of 14 single-nucleotide polymorphisms
(SNPs), previously found associated with docetaxel clearance in a cohort of lung cancer patients. We were unable to identify genes
relatedtotoxicity in thisstudy. Nevertheless, toxicity was aggravated bytheaddition ofthe tyrosinekinase inhibitor.In conclusion,
despite adequately tolerated as monotherapy, combination regimens should be carefully considered for overlapping adverse events
in order to avoid increased treatment-related toxicity.
1.Introduction
Adjuvant systemic treatment with chemotherapy has im-
provedtheoutcomeforpatientswithbreastcancer[1].How-
ever, in patients with metastatic disease, chemotherapy may
prolong survival, but the disease almost always remains in-
curable, and new therapeutic strategies are therefore needed.
Genetic aberrations and speciﬁc molecular pathways that
drive the growth and progression of tumors may pave the
way for targeted therapies, as in the case of the epider-
mal growth factor receptors. The ampliﬁcation of the Her2/
neu oncogene with c-erbB2 overexpression in a subset of
breast cancer patients is an example of this [2–4]. Breast
cancers also overexpress the epidermal growth factor recept-
or (erbB1), and the presence of this growth factor receptor
has been linked to a higher proliferative potential and a
worsened prognosis and resistance to hormonal therapy
[5]. Despite this, monotherapy inhibiting the EGF (epi-
dermal growth factor—erbB1) receptor with erlotinib or
geﬁtinib in unselected breast cancer patients has been dis-
appointing, without clinical eﬃcacy [6, 7]. Although inhi-
bition of EGFr and downstream MAPK signaling has been
demonstrated, this has not translated into a clinical response
[8]. However, enhanced eﬃcacy of chemotherapy when
combined with EGFr inhibition has been described in an
experimental setting [9] and such treatment may even result2 ISRN Oncology
in an antiangiogenic eﬀect [10]. Treatment with geﬁtinib in
combination with docetaxel was tested in two single-arm,
phase II studies with chemotherapy administered every third
week [11, 12], shortly after the initiation of our study. The
response rate in these studies was relatively high (54% and
39%, resp.). However, the absence of a comparator arm
mak esitdiﬃculttoevaluatetheseresponsedata[13,14].The
combination of chemotherapy and tyrosine kinase inhibitors
astreatmentofNSCLChasbeenstudiedwithnoapparentin-
crease in eﬃcacy in several phase III trials [15–19]. However,
chemotherapy in combination with lapatinib (an erbB-2
tyrosine kinase inhibitor) has been highly eﬀective in breast
cancer [20, 21], but not without associated toxicity. The
combination of the tyrosine kinase inhibitior and chemo-
therapy has been shown to result in side eﬀects, in particular
fromthegastrointestinaltract.Toxicitywiththedocetaxelre-
gimen given every third week is signiﬁcant, and a better tol-
erated weekly dosing regimen has consequently been intro-
duced [22–24]. This trial was therefore designed as a rando-
mized phase II study to investigate the potential eﬃcacy
and tolerability of geﬁtinib (an oral EGFR tyrosine kinase
inhibitor) in combination with weekly administrated doc-
etaxel.
2. Patientsand Methods
2.1. Patient Selection, Inclusion and Exclusion Criteria, and
Randomization. The study was planned for the inclusion
of 66 patients with metastatic breast cancer in a placebo-
controlleddouble-blindrandomizedphaseIIclinicaltrial.To
be eligible for the study, patients had to be 18 years or older,
with a histopathological diagnosis of mammary carcinoma,
measurable disease according to the RECIST criteria, and
a life expectancy of at least 3 months. The patients signed
an informed consent form, had an adequate health status
(WHO (World Health Organization) performance status
0–2) with the absence of signiﬁcant comorbidity (lung or
cardiac disease, or previous diagnosis of malignant dis-
ease other than basal cell carcinoma), a left ventricular ejec-
tion fraction of at least 50% and adequate laboratory
values (absolute neutrophil count (ANC) >1.5 × 109/liter,
total platelet count ≥100 × 109/liter, serum bilirubin ≤1.0
upper limit of reference range (ULRR), serum creatinine
≤1.5 times the ULRR, alanine amino transferase (ALT) or
aspartateaminotransferase(AST) ≤2.5timestheULRRifno
demonstrable liver metastases or ≤5 times the ULRR in the
presence of liver metastases). If alkaline phosphatase (ALP)
was >2.5 times ULRR, the alanine amino transferase (ALT)
and/or aspartate amino transferase (AST) had to be ≤1.5
times the ULRR.
Priortoinclusion,patientswererequirednottohaveper-
sistent adverse events (common toxicity criteria (CTC) grade
3o rm o r e )f r o mo t h e ra n t i c a n c e rt r e a t m e n t sa n ds h o u l dn o t
have received other treatment modalities. Previous treatment
with taxanes was not allowed unless given as a part of an
adjuvant treatment regimen more than 1 year before study
inclusion. Prior treatment with one antracycline-containing
regimen and/or endocrine therapy for metastatic breast
cancer was allowed.
A randomization scheme was prepared by the Biostatis-
tics Group, AstraZeneca, and the patients allocated a rando-
mization code strictly sequentially from the pharmacy when
entering the study. All information on study drug resided at
the pharmacy, including codebreak envelopes to be used in
case of medical emergency.
The study was approved by the institutional protocol
review board, the regional ethics committee, the Norwe-
gian Medicines Agency and was carried out in accordance
with the Declaration of Helsinki, International Conference
on Harmony/Good Clinical practice and AstraZeneca’s
policy on Bioethics. The study was registered in the
http://www.ClinicalTrials.gov/ database with the identiﬁer
NCT00319618.
2.2. Treatment Plan. The patients were randomized to
receive geﬁtinib 250mg or a matched placebo tablet once
daily during participation in the study. In each seven-week
treatment cycle, the patients were given docetaxel every
week for six weeks, followed by a one-week treatment rest.
Docetaxel was administered at a dose of 35mg/m2,a f t e r
premedication with dexamethasone given as an IV infusion
30 minutes before administration of chemotherapy. The pa-
tients received 8mg dexamethasone prior to the ﬁrst and
second infusion of docetaxel, and the dose was thereafter
reduced to 4mg dexamethasone. The patients were assessed
weekly for adverse events, WHO performance status, and
vital signs. Tumor evaluation was performed after each sev-
en-week cycle, and the patients continued on study medica-
tion until disease progression or the appearance of unaccept-
able toxicity.
2.3. The Outcome Variables, Evaluation of Tumor Response,
and Toxicity Assessment. The primary endpoint of the study
was objective tumor response (complete response (CR) or
partial response (PR)) according to RECIST criteria in the
twotreatmentgroups.Thesecondaryendpointsweretimeto
progression and duration of response. All evaluations were
performed according to the RECIST criteria, and all sym-
ptomsoftoxicityweregradedaccordingtotheNationalCan-
cer Institute common toxicity criteria (CTC version 2.0).
The baseline evaluations were performed within 21 days
of the inclusion and randomization, and the patients were
evaluated after every (7-week) cycle. Patients with skin rash
were allowed dose interruptions in the study medication
(geﬁtinib or placebo) for up to 14 days, and supportive ther-
apy such as antibiotics, steroid creams, and antihistamines
were administered. In patients with diarrhoea CTC grade 3
or 4, and/or a reduction in ANC, the study medication (geﬁ-
tinib or placebo) was interrupted until recovery or up to 14
days. Patients unable to restart study medication after this
period were taken oﬀ the study.
Before the start of a new cycle, the patients were
requiredtohaveadequatehealthstatusandlaboratoryvalues
(as described in the inclusion and exclusion criteria in
Section 2.1). Otherwise, the treatment was delayed until re-
covery. Patients experiencing treatment delays were retreated
after recovery with docetaxel 30mg/m2,e x c e p tf o rp a t i e n t sISRN Oncology 3
withneutropenialastinglessthan7days.Thesepatientswere
retreated at the same dose.
Patients experiencing persistent emesis CTC grade 4,
diarrhoea CTC grade ≥3 or peripheral neuropathy grade 2
wereretreatedwithdocetaxelat30mg/m2 uponrecovery.Pa-
tients with more severe side eﬀects or persistent toxicity
despite dose reductions were withdrawn from the study. Pa-
tients suspected to have interstitial lung disease (ILD) were
immediately taken oﬀ the study medication. If ILD was con-
ﬁrmed, the patient was withdrawn from the study.
2.4. Hypothesis, Statistical Analysis, and Patient Number
Calculations. To warrant further evaluation, the response
rate for the geﬁtinib plus docetaxel treatment arm must be
at least 5% greater than the placebo arm. It is hypothesized
thatgeﬁtinibmayincreasetheobjectiveresponserateby20%
over docetaxel alone, an objective response rate for docetaxel
of 35% versus 55% for geﬁtinib plus docetaxel. Assuming the
hypothesis is true, the goal of the trial is to have a probability
of 0.90 of satisfying both criteria. This study design will
require 66 patients (33 per arm) [25].
2.5. SNP Analysis. A panel of 14 SNPs in 12 genes (see
supplementary Table 1 in Supplementary Material available
online at doi:10.5402/2012/176789) previously found to be
signiﬁcantly associated with the clearance of docetaxel in a
group of non-small-cell lung cancer (NSCLC) patients were
genotyped in this sample set [26]. The SNPs were originally
part of a panel of 1030 SNPs genotyped in 193 cancer pa-
tients, including the NSCLC patients. The biological justiﬁ-
cation for our SNP selection in the original panel is
thoroughly described in [27] but can in brief be described
as SNPs in genes of relevance for the metabolism of reactive
oxygenspecies(ROS)ortheresponsetoROS.TheSNPswere
genotyped using the 7900HTFast Real-Time PCR System
(Applied Biosystems, Foster City, CA), using the standard
assay conditions for the Applied Biosystems assay (assay ID
g i v e ni ns u p p l e m e n t a r yT a b l e1 ) .O n eo ft h eS N P sc o u l dn o t
be genotyped due to failure of the assay design—probably
due to large repeat areas in the DNA sequence around the
SNP. The DNA genotyped was isolated from either blood
or tumor tissue using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) and applying the recommended protocol
for FFPE (formalin ﬁxed paraﬃn embedded) tissues.
2.6. Statistical Analysis—SNP Studies. The association be-
tween individual SNPs and the clinical endpoints was anal-
ysed using standard chi-square tests included in SPSS v15.0.
P-values are two sided and not adjusted for multiple testing.
To assess the combinatorial eﬀect of multiple SNPs, leave-
one-out cross-validation (LOOCV) analysis implemented in
Bioclassiﬁer [28] was utilized. For the LOOCV analysis the
clinical parameters needed to be grouped into two groups.
This was done, in advance, as described here: treatment re-
sponse (partial response (PR) and stable disease (SD) versus
progressive disease (PD)); WHO score (independent of time
point: WHO 0 and 1 versus WHO 2 and WHO 3). The clini-
cal end-point toxicity was already deﬁned as a two-category
variable (±toxic response).
Table 1: Patient demography at screening.
Docetaxel alone
(n = 9)
Geﬁtinib + docetaxel
(n = 9)
Age (range; years) 53.1 (35–69) 56.3 (37–67)
Weight/height 70.4kg/164cm 70.4kg/164cm
Performance status
WHO grade 0 5 4
WHO grade 1 3 4
WHO grade 2 1 1
Previous therapy for
metastatic disease
None 1 5
Endocrine therapy 6 3
Antracycline 1 1
No bias for the SNPs studied with regards to tissue
type genotyped (blood or tumor) or treatment administered
existed for the SNPs except rs1078985 and rs2230949, where
one of the alleles was less frequent in the tumors suggesting
LOH in the locus (P-value 0.048 and 0.041, resp.). No bias
was found with regards to treatment regimen or clinical
end-points (toxic reaction, WHO score, and treatment re-
sponse—PR, SD, or PD).
3. Results
3.1. Patient Demography and Previous Treatment. At o t a lo f
18 patients were included in this study. Nine patients were
randomized to receive geﬁtinib 250mg QD and nine to re-
ceive a matched placebo preparation. All patients started
treatmentwithdocetaxel35mg/m2 given as weekly infusions
for 6 weeks, followed by a one week without treatment,
before the start of a new cycle.
The patient demography was similar in the geﬁtinib
and placebo group, with respect to age and height/weight
(see Table 1). Only one patient in each treatment group
had received previous chemotherapy for metastatic disease,
whereas six patients in the placebo group and three patients
inthegeﬁtinibgrouphadreceivedendocrinetherapyforme-
tastatic disease. The performance status at study inclusion
did not diﬀer, as shown in Table 1.
3.2. Study Treatment and Study Discontinuation. The pa-
tientsrandomizedtothecombinedtreatmentgroupreceived
a median of 40 doses of geﬁtinib tablets (range 16–130),
whereas the median number of received doses for the control
patients was 84 doses of placebo tablets (range 11–161).
Fifty-four infusions of docetaxel were planned in each group
of patients in each seven-week treatment cycle. However, the
patients randomized to receive geﬁtinib were given 46, 21,
and5infusionsintheﬁrst,second,andthirdtreatmentcycle,
respectively. The corresponding numbers for the patients
in the placebo arm were 50, 40, and 25. Only one patient
in the study, randomized to the placebo arm, was started
on cycle four, but did not ﬁnish this treatment cycle. The
patients in the combined treatment group received a median4 ISRN Oncology
Table 2: Common adverse events during treatment.
Event Docetaxel alone (n) Geﬁtinib + docetaxel (n)
Diarrhoea 8 8
Nausea 8 5
Vomiting 5 3
Fatigue 8 9
Rash 4 6
n: number of patients experiencing adverse event.
of 7.1 weeks of chemotherapy, while the patients treated with
chemotherapy alone were given such therapy for 18 weeks
(median).
Three patients in the geﬁtinib-treated group were taken
oﬀ the study due to treatment-related toxicity, and the
treatmentfortwoofthesepatientswasterminatedintheﬁrst
treatment cycle. In the placebo-treated group, four patients
were discontinued due to toxicity, one in the ﬁrst treatment
cycle. Correspondingly, six and ﬁve patients, receiving geﬁ-
tinib or placebo in combination with docetaxel, respective-
ly, were taken oﬀ the study medication due to objective
progression of the disease.
Duetothetoxicityseenwhileontreatment,thestudywas
discontinued after accrual of 18 of the planned 66 patients in
the study.
3.3. Clinical Response and Time to Tumor Progression. One
patient treated with geﬁtinib and four patients in the place-
bo-treatedgroupexperiencedapartialresponseonthethera-
py given. All the responses were conﬁrmed and lasted for
more than one treatment cycle. The time to tumor pro-
gression was median 93 and 131 days (intention-to-treat
population), in the geﬁtinib and the placebo-treated group,
respectively. Signiﬁcance testing was not possible due to the
small number of patients included.
3.4. Toxicity and Adverse Events. The most commonly en-
countered adverse events (seen in more than 50% of the
patients in either treatment group) are listed in Table 2.
Seven patients in each treatment group experienced CTC
grade 3 adverse events. One patient in the placebo-treated
group had a CTC grade 4 neutropenia during the treatment.
Six geﬁtinib-treated, but only two placebo-treated, patients
experienced a grade 3 fatigue. Other than fatigue, gastroin-
testinal disorders (diarrhoea, nausea, vomiting, and stomati-
tis) were the most frequent causes of grade 3 adverse events
and were seen in three placebo- and four geﬁtinib-treated
patients. Grade 3 dehydration and electrolyte disturbances
were seen in four patients treated with geﬁtinib, but not in
patients treated with placebo. One patient treated with ge-
ﬁtinib was found to have a deep vein thrombosis, and one
placebo-treated patient had a subclavian vein thrombosis,
both CTC grade 3 events.
The general status of the patients diﬀered between the
groupsduringtheﬁrsttreatmentcycle,reﬂectedintheWHO
performance status reported. After four weeks in the study,
none of the patients treated with geﬁtinib and docetaxel
remained in the WHO grade 0 category, and at the end of
Table 3: Serious adverse events.
Event Docetaxel alone
(n = 3)
Geﬁtinib + docetaxel
(n = 5)
Dehydration 0 3
Fatigue 0 1
Stomatitis 0 1
Diarrhoea 3 2
Hypokalemia 0 1
Anorexia 1 0
Vomiting 1 0
Neutropenia 0 1
Pneumonia 0 1
Infection 0 1
Catheter sepsis 0 1
Chest pain 0 1
Subclavian vein
thrombosis 10
Vertigo 1 0
n: number of patients.
the treatment cycle, four patients had a WHO grade 2 per-
formance status. The patients treated with placebo and
docetaxel had a better performance status with three patients
on WHO grade 0 at 4 weeks and none experiencing a grade
2 (or worse) performance status at the end of the treatment
cycle.
Five patients treated with geﬁtinib and docetaxel and
three patients treated with placebo and docetaxel were re-
ported with serious adverse events (SAEs—see Table 3). The
majority of the serious adverse events were linked to the
occurrence of diarrhoea, reduced oral ﬂuid and food intake
and ﬂuid loss in four patients treated with geﬁtinib and do-
cetaxel and two patients treated with placebo and docetaxel.
All these patients needed supportive hospitalization. For one
patient in each treatment group, multiple SAEs were re-
ported, with two events for the patient treated with geﬁtinib
and three events for the placebo-treated patient.
The SAEs in the patients treated with geﬁtinib and
docetaxel, experiencing catheter sepsis and pneumonia, were
not considered related to the study medication. This was also
thecaseforthepatientwithsubclavianveinthrombosis,who
received placebo and docetaxel.
3.5. SNP Analysis. Due to the relatively large proportion of
patients with adverse events in both the geﬁtinib- and place-
bo-treated groups, we wanted to investigate if the toxicity
seen could be related to genotypic determinants of docetaxel
metabolism. For this study, we used a panel of 13 SNPs in 12
genes, identiﬁed in a previous study where these SNPs were
tested in a serie of 24 non-small-cell lung cancer patients
treated with docetaxel [26]. These SNPs were associated with
the clearance of docetaxel in these patients and were found
in genes related to the metabolism of or response to reactive
oxygen species.ISRN Oncology 5
Table 4: Classiﬁcation results from the LOOCV analysis∗.
Patient ID Response
LOOCV analysis
True class Classiﬁed as
12 S D + P R S D + P R
2 3 PD PD
31 S D + P R S D + P R
42 S D + P R S D + P R
52 S D + P R S D + P R
6 3 PD PD
72 S D + P R S D + P R
81 S D + P R S D + P R
91 S D + P R S D + P R
10 2 SD + PR SD + PR
11 2 SD + PR SD + PR
12 3 PD SD + PR
13 1 SD + PR SD + PR
14 3 PD SD + PR
15 1 SD + PR SD + PR
16 3 PD PD
17 2 SD + PR SD + PR
18 2 SD + PR PD
∗Patient IDs given in bold are correctly classiﬁed with regards to response
group in the analysis.
3.5.1.AssociationbetweenIndividualSNPsandToxicity. Ana-
lyzing the genotype distribution of the 13 studied SNPs sep-
arately against the clinical end-points revealed two associa-
tions with borderline signiﬁcance: (1) the association be-
tween the SNP rs701992 in NDUFB4 (NADH dehydrogenase
(ubiquinone) 1 beta subcomplex, 4) and the WHO score at
0 weeks of treatment (P-value 0.055) and (2) the associa-
tion between the SNP rs1341164 in CYP2C8 (Cytochrome
P4502C8) and the WHO score at 8 weeks of treatment (P-
value 0.044). In both cases there is a higher frequency of
the mutated allele in the groups with higher scores for the
clinical end-points. The genotype distribution of these SNPs
associated with the WHO performance status at before treat-
ment (SNP rs701992) and after 8 weeks of therapy (SNP
rs1341164) can be found in supplementary Table 2.
3.5.2. Combinatorial Impact of the Genotyped SNPs on
Response Using LOOCV Analysis. To assess the collective im-
pact of multiple SNPs on the clinical end-points we per-
formed a leave-one-out cross-validation analysis [28]. For
the clinical end-point response we combined the patients in
two groups: either partial response or stable disease (PR/SD)
or progressive disease (PD). Our panel of SNPs correctly
classiﬁed the response in these two groups in 83.3% of the
samples (n = 15, Table 4). More close analysis at the LOOCV
(leave one out cross validation analysis) result points to the
rs2228001 in XPC (xeroderma pigmentosum complemen-
tation group C) gene contributing mostly to this predictive
potential. To further investigate this association with an
alternative statistical method, a chi-square analysis in the
Table 5: Genotype distribution of rs2228001 in the treatment
response categories partial response/stable disease versus progres-
sive disease∗.
Clinical end-point Genotype distribution
GG GT TT P value
PR + SD 5 (38.5) 7 (53.8) 1 (7.7)
PD 1 (20.0) 1 (20.0) 3 (60.0) 0.057
∗Number in brackets indicate percentages within each clinical level.
same two-response groups was performed, and a higher fre-
quency of the T allele in the group with progressive disease
was observed (P = 0.057, Table 5).
4. Discussion
The aim of this study was to investigate the feasibility and
activity of combining the oral tyrosine kinase inhibitor geﬁ-
tinib with docetaxel. The tolerability of chemotherapy has
generally been improved by the introduction of weekly based
dosing regimens, as demonstrated for both paclitaxel and
docetaxel with no reduction in eﬃcacy (for review see [29]).
Geﬁtinib dosed daily at 250mg is very well tolerated and has
also been extensively studied in combination with diﬀerent
chemotherapeutic regimens in many disease settings [30].
However, despite an excellent safety proﬁle of these agents
whengivenalone,theadditionofothertherapiesmaychange
the tolerability of the chemotherapy treatment. In our study,
the majority of adverse and serious adverse events were
related to ﬂuid balance, ﬂuid intake, and dehydration and
other gastrointestinal side eﬀects, as described previously
for weekly treatment regimens [22, 29]. Only one patient
experienced neutropenia as a serious adverse event. This is
in contrast to the two published studies on the combined
treatment with geﬁtinib and docetaxel given every third
week [11, 12]. In these studies, neutropenia associated with
chemotherapy administration was the most frequent adverse
event. Severity of neutropenia was grade 3 or 4, aﬀecting 43
and 49% of the patients, respectively. In one of the studies,
the patients were allowed to continue in the study until
disease progression or other causes for withdrawal, and 30%
of the patients discontinued the treatment due to toxicity
[12]. In the other study by Ciardiello et al., the patients were
allowed treatment for up to 6 cycles (36 weeks) of combined
therapy; thereafter geﬁtinib monotherapy was administered
to patients experiencing a clinical response [11]. The median
number of chemotherapy cycles in these studies was 5.6
and 5.2, respectively, corresponding to 16.8- and 15.5-weeks
treatment duration. In our study, the patients in the placebo
group were given chemotherapy for 18 weeks (median),
comparable to the previously mentioned studies, while the
patients treated with geﬁtinib received chemotherapy for 7.1
weeks (median). Despite this, patients who discontinued due
to toxicity were present in each group (four in the placebo-
treated group at 3.4, 13.4, 18, and 22 weeks, and three in
the geﬁtinib group at 2, 5, and 19.7 weeks). The reason for6 ISRN Oncology
the short treatment period in the geﬁtinib treatment group is
therefore both due to patients experiencing toxicity and pro-
gression of the disease, and not only caused by the combined
treatment with geﬁtinib and docetaxel. The reported WHO
performance status was also worsened in patients treated
with the chemotherapy/geﬁtinib combination. Whether this
is due to the treatment is uncertain, as the time to tumor
progression was shorter in the geﬁtinib/docetaxel treated
patients, and a clinical deterioration may have resulted in a
worsened performance status.
However, the fact that the patients in the geﬁtinib group
reporting fatigue grade 3 and dehydration and electrolyte
disturbances (also grade 3) were only found in the geﬁtinib
treatment group (four patients) may indicate an increased
toxicity of combined treatment with docetaxel and geﬁtinib.
This is also supported by the serious adverse events observed
(see Table 3). However, the number of patients is small and
the results should therefore be interpreted with caution.
The increased tolerability of weekly dosed chemotherapy
is mainly associated with a reduction of hematologic side
eﬀects, but other nonhematologic adverse events may be-
come more important when combination therapy is intro-
duced, as seen in our study. Treatment with geﬁtinib seemed
to be less well tolerated when given in combination with
docetaxel dosed weekly (our study) compared to the every
third-week dosing regimens [11, 12].
Patients treated with geﬁtinib had a shorter time to
tumor progression, and only one of these patients experi-
enced a partial response, compared to four patients treated
with weekly docetaxel alone. Due to the small number of pa-
tients treated, it is not possible to evaluate the eﬃcacy and
activity of the geﬁtinib/docetaxel combination. Although
some studies have reported eﬃcacy of the combined treat-
ment with geﬁtinib and docetaxel [11, 12], the role of
geﬁtinib in obtaining these responses is not clear, and further
clinical studies are needed to address this question.
In a study investigating the inﬂuence of 550 SNPs on do-
cetaxel clearance in 24 patients with NSCLC treated at our
institution, a number of SNPs were found to be associated
with docetaxel clearance [26]. To study whether these results
could predict the response or toxicity seen in our patients,
we genotyped the cohort for the presence of these SNPs. Two
SNP rs701992 in NDUFB4 and rs1341164 in CYP2C8 were
found weakly associated with WHO score at 0 and 8 weeks
of treatment, respectively (see supplementary Table 2). One
SNP, rs2228001, in XPC was found at higher frequency of
the T allele in the group with progressive disease. The results
must be interpreted with caution, due to the limited number
of patients included into the present study, and do not
give an answer to the question of the predictive value of
such a panel of SNPs. The XPC gene, giving the predictive
potential, encodes a key protein in the nucleotide excision
repair (NER) pathway, and a recent study has linked the
presence of T in this allele (Ala499Val) to a reduced DNA
damage and treatment response in vitro [31]. Other studies
have identiﬁed the XPC gene to be changed after treatment
[32], and that genetic variation may inﬂuence the risk of
recurrenceaftertreatmentformalignantneoplasms[33],but
little is known about the eﬀect of such genetic variants on
docetaxel and/or geﬁtinib sensitivity, and further studies are
needed to clarify this.
Association between survival and metabolism genotype
has been shown in patients treated with anthracyclines and
cyclophosphamide [34, 35]. Docetaxel is metabolized by
the cytochrome P450 system, and in particular the CYP3A
enzymes[36].Drugslikedocetaxelandgeﬁtinib,whichshare
thesamemetabolicpathway,mayinﬂuencethebreakdownof
each other in vivo, increasing the drug concentrations. This
could aﬀect both the toxicity and eﬀect of the drugs [37].
However,associationsbetweengeneticvariantsoftheCYP3A
enzymes and the eﬀect of docetaxel have not, to our knowl-
edge, been found, although pharmacogenomic studies have
been published investigating the possible inﬂuence of gen-
eticvariantsonthedocetaxelmetabolism[38–40].Thegene-
ticvariantsoftheCYP3Aenzymeshavenotbeeninvestigated
in this study, and a relationship between such variants and
the observed toxicity cannot be excluded. However, the
number of patients in our study is small, and larger stud-
ies with more patients are needed for obtaining reliable con-
clusions about such a relationship.
In conclusion, the weekly dosing regimen of docetaxel
used in our study did not improve the treatment tolerability,
as expected from other publications and our clinical experi-
ence. Although the majority of the toxicity most likely is due
to the chemotherapy treatment alone, treatment with geﬁ-
tinibmayhavecontributedandaggravatedthetoxicity.Some
of the patients treated with the combination regimen experi-
enced dehydration and electrolyte disturbances not seen in
patients treated with chemotherapy alone and not seen in
patientstreatedwiththesamedruginotherdosingregimens.
Geﬁtinib has been successfully combined with other thera-
pies (hormonal therapy and chemotherapy), without severe
combinedtoxicity[30].Nevertheless,increasedgastrointesti-
nal toxicities and rash have been observed. In the planning
of clinical studies with apparently well-tolerated targeted
therapies in combination with chemotherapy, the possibility
of overlapping adverse events should be carefully considered
to avoid increased toxicity of the treatment regimen.
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